RxDoctor Payments Data

Munir Shah, MD

Internal Medicine · Maumee, OHNPI 1437240611

Payments from drug & device makers

$8,313in general payments, 2019–2025

Across 93 payments — averaging $89.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$7K
  • Merck$412
  • Gilead$341
  • Inspire Medical Systems, Inc.$142
  • Viiv Healthcare Company$138
  • Tetraphase Pharmaceuticals, Inc.$136
  • plus $550 from 14 others

What the payments were for

  • Speaking & faculty fees$5,00060%
  • Travel & lodging$7249%
  • Food & beverage$2,53931%
  • Education$380%
  • Gifts$120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,313 in reported general payments places this provider in the 90th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$200,892
Medicare patients
294
Services billed
2,245

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala26$119,522
DovatoDolutegravir Sodium/Lamivudine11$38,113
Vancomycin Hcl32$9,428
CeftriaxoneCeftriaxone Sodium34$8,233
Cefepime Hcl15$5,637
Meropenem16$4,139
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam11$3,781
Doxycycline Hyclate71$2,567
Cephalexin70$1,169
Cefazolin Sodium11$750
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim29$698
Azithromycin19$316
Fluconazole18$246
Amoxicillin15$88

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$341$119,52226 claims
Viiv Healthcare CompanyDovato$138$38,11311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Maumee

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →